Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on June 27, 2007
JNCI Journal of the National Cancer Institute 2007 99(13):983-985; doi:10.1093/jnci/djm042
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
99/13/983    most recent
djm042v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Dreher, M. R.
Right arrow Articles by Chilkoti, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dreher, M. R.
Right arrow Articles by Chilkoti, A.
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published by Oxford University Press 2007.

EDITORIALS

Toward a Systems Engineering Approach to Cancer Drug Delivery

Matthew R. Dreher, Ashutosh Chilkoti

Affiliations of authors: Diagnostic Radiology Department, Clinical Center, National Institutes of Health, Bethesda, MD (MRD); Department of Biomedical Engineering, Duke University, Durham, NC (AC)

Correspondence to: Ashutosh Chilkoti, PhD, Department of Biomedical Engineering, Duke University, Durham, NC 27708 (e-mail: chilkoti@duke.edu).

The first 150 words of the full text of this article appear below.

As illustrated by Tang et al. (1) in this issue of the Journal, the treatment of solid tumors may be improved by controlling the pharmacologic properties of anticancer therapeutics. In 1906, Paul Ehrlich established the concept of drug delivery (2) by proposing a carrier that would "bring therapeutically active groups to the organ in question." The objective of drug delivery in the treatment of solid tumors is to increase the concentration of a therapeutic agent in the tumor while limiting systemic exposure (3–5). Increasing the concentration of drugs in the tumor relative to normal tissues results in improved tumor control and reduced toxic side effects. Numerous drug delivery technologies have been developed to accomplish this objective, including liposomes (6), micelles (7), antibody-directed enzyme–prodrug therapy (8), photodynamic therapy (9), affinity targeting (10), and . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

Improving Penetration in Tumors With Nanoassemblies of Phospholipids and Doxorubicin
Ning Tang, Gangjun Du, Nan Wang, Chunchun Liu, Haiying Hang, and Wei Liang
J Natl Cancer Inst 2007 99: 1004-1015. [Abstract] [Full Text] [PDF]

IN THIS ISSUE
J Natl Cancer Inst 2007 99: 981. [Extract] [Full Text] [PDF]

Press Release: Nanoparticles Carry Chemotherapy Drug Deeper into Solid Tumors
Liz Savage
J Natl Cancer Inst 2007 99: 981. [Extract] [Full Text]